ReViral’s RV521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms
Mon, 05/02/2018 - 07:30
Wed, 13/12/2017 - 10:00
13th December 2017 / Sciad Newswire / Amyndas Pharmaceuticals, which is committed to developing innovative therapeutics for
Thu, 09/11/2017 - 07:30
Cambridge, UK, 9th November 2017 / Sciad Newswire / Cypralis, in collaboration with the University of Liverpool, will prese
Tue, 26/09/2017 - 00:15
New approach informed by government priorities, consultancy with industry and the NHS, and a century of expertise
Tue, 05/09/2017 - 07:30
Challenge trial will evaluate RV521 in approximately 70 volunteers
Thu, 20/07/2017 - 10:59
Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US trial of its MiCheck® prostate cancer screening test.
Thu, 29/06/2017 - 07:30
Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
Wed, 14/06/2017 - 07:30
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks.
Mon, 15/05/2017 - 10:00
London, UK, 15th May 2017 / Sciad Newswire / Orthonika Limited, a spin-out from Imperial College London, is pleased to ann
Mon, 24/04/2017 - 07:30
Phase 2a RSV Challenge Study Planned for Q3 2017